Resolvin E1 (TP-317) treatment for pancreatic cancer
Official title: Development of a Novel Resolvin-Based Therapy for Treatment of Pancreatic Cancer
Funded at Thetis Pharmaceuticals, LLC · NIH-11351574 · Data updated 2026-11-12
This project is developing a new drug called TP-317, based on a natural molecule (Resolvin E1), to reduce tumor growth and tumor-related inflammation in people with pancreatic cancer.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thetis Pharmaceuticals, LLC NIH-funded |
| Lab location | 1 site (Deep River, United States) |
| Project start | June 2, 2023 |
| Project end | May 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $1,725,203 |
| NIH project number | 4R44CA278026-02 |
| Project ID | NIH-11351574 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be people with pancreatic cancer—particularly those with advanced or chemo-resistant disease—though this grant supports preclinical work and any patient participation would occur later in clinical trials.
✕Less likely to help
People without pancreatic cancer, or those seeking an immediately available treatment, will not benefit from this preclinical program until human trials are completed and the drug is approved.
What this research studies
Researchers are developing TP-317, a drug based on Resolvin E1 that helps clear dead cell debris and calm harmful inflammation in tumors. Early animal studies show TP-317 can slow tumor growth, boost anti-tumor immune responses, and add benefit when given with chemotherapy. This R44 grant funds key preclinical safety, dosing, and efficacy studies in animals needed to support an IND application. If those studies succeed, TP-317 could move into human clinical trials for people with pancreatic cancer.
Why it matters
Potential benefit: If successful, TP-317 could slow tumor growth, improve the immune response against pancreatic tumors, and make chemotherapy more effective, potentially improving survival and reducing side effects.
How similar studies have gone: Related laboratory and animal studies show Resolvin E1 can reduce inflammation and suppress tumors and may boost chemotherapy effects, but human benefit has not yet been proven.
Where this research is happening
-
Thetis Pharmaceuticals, LLC
Deep River, United States Active
Researchers
- Principal investigator: Parkinson, John — Thetis Pharmaceuticals, LLC
- Study coordinator: Parkinson, John
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.